Priority 4 from the Myeloma (Canada) PSP
| UNCERTAINTY: What are new treatments for myeloma patients that will improve life expectancy with fewer adverse side effects (e.g., pain, nausea, neuropathy, immune suppression)? (JLA PSP Priority 4) | |
|---|---|
| Overall ranking | 4 |
| JLA question ID | 0113/4 |
| Explanatory note | Participants are eager for new treatments at all stages of the disease that will improve the progression-free and overall survival; minimize the side effects of treatment, such as pain, nausea, neuropathy, and immune supression; and improve their quality of life. |
| Evidence |
No evidence identified |
| Health Research Classification System category | Cancer and neoplasms |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | More treatment options are needed, I think, as our doctor says there are only 5 drugs. ~ Can we get a drug that does not cause a multitude of side effects that impact quality of life. ~ life expectancy improvements thru new drug therapy. ~ Create drugs that don't have such awful side effects. ~ Extension of survival through new treatments? ~ Continue research into new therapies and improve therapies and medications that have been successful. ~ Finding treatment meds that don't have to suppress your immune system. |
| Submitted by | Please see the PSP Engagement Summary on the JLA website |
| PSP information | |
|---|---|
| PSP unique ID | 0113 |
| PSP name | Myeloma (Canada) |
| Total number of uncertainties identified by this PSP. | 59 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 28 April 2021 |